The Power of Low Lifelong LDL-C

A high-impact genetic association study found that people with certain genetic variants were 50% less likely to develop coronary heart disease. The findings reveal the importance of maintaining low LDL-C (or “bad” cholesterol) levels over a lifetime.

Pharmacological LDL-C management may reduce the risk of developing CHD by 22%, but this study found that people who had variations in either APOB or PCSK9 (two genes known to be associated with LDL-C) were even more protected against CHD. 

The authors combined genetic and clinical data from more than 200,000 participants from 5 NHLBI prospective cohorts and the UK Biobank. Of these, 139 (0.7%) carried a truncating mutation in either APOB or PCSK9–switching these genes off. 

Over a median of 21.5 years…

  • A CHD event (like a heart attack or death) was far less likely in APOB or PCSK9 variation carriers than noncarriers (8.6% vs. 16%), corresponding to a 49% reduced CHD risk (HR: 0.51). 
  • Carriers had a 45 to 49 mg/dL lower average untreated LDL-C level. 

To put the magnitude of the 49% reduced CHD risk into perspective, here is how traditional risk factors affected the likelihood of developing CHD. 

  • No diabetes reduced risk by 53%
  • No hypertension reduced risk by 25%
  • Not smoking reduced risk by 43%. 

That’s right: a APOB or PCSK9 variation carrier who smokes is more protected against CHD than a noncarrier who does not smoke. 

The Takeaway
Analysis of DNA variants that turn off APOB or PCSK9 revealed the power of lifelong low LDL-C. For LDL, it’s not only about how low the levels are, but for how long those levels have stayed low.

Get the top cardiology stories right in your inbox

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team